Home Tags HER2-targeting

Tag: HER2-targeting

The Highs, Lows, and Resurgence of Antibody-drug Conjugates

Antibody drug conjugates (ADCs) offer a way to deliver a cytotoxic or an immuno-stimulatory payload directly to tumors to maximize the anti-tumor efficacy of the payload with reduced systemic toxicities. The development of ADCs has occurred over several decades. ADCs have been through several highs and lows where there was substantial excitement for the promise ADCs hold only to be followed by disinterest when there were disappointing results in the clinic. This resulted in several companies abandoning their internal ADC development efforts. Twelve ADCs globally have been approved to treat hematologic or solid tumors. The renewed interest in ADCs, is due, in part, to the recent clinical success of ADCs, the development of improved ADC technologies, and the identification of new ADC targets.

Initial Results from Phase I Trial with anti-HER2 ADC SYD985 Shows...

Researchers working for Dutch pharmaceutical company Synthon Biopharmaceuticals based in Nijmegen, The Netherlands, report positive initial results from the dose-escalation part of its ongoing first-in-human trial...

X